Company News
Connect with us at BIO International Convention Digital Event 2021!
Updates for A166 (HER2 ADC) will be presented at 2022 ASCO Annual Meeting
Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.
May 29, 2022
KLUS Pharma is Attending BIO International Convention in San Diego!
KLUS Pharma will attend 2022 BIO International in San Diego from June 13-16.
May 15, 2022
KLUS Pharma is Attending BIO-Europe Spring 2022
KLUS Pharma will attend BIO-Europe Spring to be held virtually from March 28-31, 2022.
March 1, 2022
KLUS Pharma is Attending 40th Annual J.P. Morgan Health Care Conference
KLUS Pharma will attend the 40th Annual J.P. Morgan Health Care Conference to be held virtually from January 10-13, 2022
January 1, 2022
KLUS Pharma is Attending 2021 BioPharm America Digital Conference
KLUS Pharma will attend 2021 BioPharm America Digital Conference held from September 20-23.
September 10, 2021
Kelun-Biotech Will Present an Update on SKB264 at 2021 ESMO
Kelun-Biotech will present an oral update on SKB264 at 2021 ESMO Annual Meeting held from September 16-21.
September 10, 2021
KLUS Pharma is Attending BIO International Convention Digital Event
KLUS Pharma will attend BIO International Convention Digital 2021 from June 14-18.
May 20, 2021
Kelun-Biotech Will Present Updates for A166 at ASCO
Kelun-Biotech will attend and present at ASCO 2021 for A166, an anti-HER2 ADC.
May 20, 2021
Kelun-Biotech and Ellipses Pharma Announce a Licensing Agreement for A400
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics
March 26, 2021
KLUS Pharma is Attending BIO-Europe Spring
KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.
March 5, 2021
KLUS Pharma is Attending BIO Partnering at JPM
KLUS Pharma will attend BIO Partnering at JPM Digital Event held on January 11-15, 2021.
December 5, 2020
IND for KL-A289 is Approved in China
The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.
September 2, 2020